{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:49:33Z","timestamp":1782452973337,"version":"3.54.5"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer-related fatigue results from competition between the metabolic demands of the tumor and those of skeletal muscles. This competition leads to an energy metabolism deficit, which is worsened by the detrimental effects of cancer therapy on mitochondrial function. Mitokines, such as Fibroblast Growth Factor 21 (FGF21), produced under these conditions help tissues adjust their metabolism to cope with cellular stress. However, the metabolic changes they trigger can be harmful if these alterations persist and become uncontrolled. Although FGF21 is involved in the metabolic adaptations needed for physical exercise, its potential role in cancer-related fatigue has not yet been studied. FGF21 has low affinity for FGF Receptors (FGFRs) and requires the co-receptor Beta-Klotho (KLB) to act in tissues such as the liver, adipose tissue, and brain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To determine whether FGF21 is produced in response to cancer and its therapy, FGF21 levels were measured in the plasma using ELISA and in the liver by quantitative real time polymerase chain reaction (qRT-PCR) in male mice administered a human papilloma virus-related head and neck cancer tumor cell line or treated with the chemotherapeutic agent cisplatin. To examine the role of FGF21 in cancer-related fatigue, tumor-bearing male mice or cisplatin-treated male mice trained to run on a wheel were given an analog of FGF21 (LY2405319) and a \u03b2-klotho antagonist (peptide-19). Behavioral fatigue was assessed by the reduction in voluntary wheel running caused by these interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both tumor growth and cisplatin increased circulating FGF21 levels and liver mRNA expression of FGF21. Chronic administration of LY2405319 at two doses did not affect wheel running in healthy mice. In contrast, administration of peptide 19 worsened behavioral fatigue caused by tumor progression and had a similar negative effect on behavioral fatigue in cisplatin-treated mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>By demonstrating that blocking activation of \u03b2-klotho, a co-receptor for FGF21 and other fibroblast growth factors, exacerbates cancer-related fatigue, the present findings underscore the significance of the production of these endocrine signals in enabling mice to maintain physical activity when their energy metabolism is compromised by cisplatin chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1800474","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:43:37Z","timestamp":1782452617000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Antagonism of \u03b2-klotho signaling by peptide 19 impairs wheel running in male mice and potentiates the cisplatin-induced decrease in wheel running"],"prefix":"10.3389","volume":"17","author":[{"given":"Brandon M.","family":"Chelette","sequence":"first","affiliation":[{"name":"Department of Symptom Research, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]},{"name":"Baylor College of Medicine","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Symptom Research, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinenye","family":"Chidomere","sequence":"additional","affiliation":[{"name":"Department of Symptom Research, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"DiMarchi","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Indiana University Bloomington","place":["Bloomington, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Indiana University Bloomington","place":["Bloomington, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dantzer","sequence":"additional","affiliation":[{"name":"Department of Symptom Research, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"123940","DOI":"10.1016\/j.lfs.2025.123940","article-title":"The role of FGF21 in the metabolic adjustments required for physical capacity","volume":"380","author":"Abe","year":"2025","journal-title":"Life Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e13770","DOI":"10.1111\/acel.13770","article-title":"Mitochondrial stress and mitokines in aging","volume":"22","author":"Burtscher","year":"2023","journal-title":"Aging Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bbi.2022.11.008","article-title":"The GDF15-GFRAL axis mediates chemotherapy-induced fatigue in mice","volume":"108","author":"Chelette","year":"2023","journal-title":"Brain Behav. Immun."},{"key":"B4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3389\/fphar.2020.00241","article-title":"SIRT1 mediates effects of FGF21 to ameliorate cisplatin-induced acute kidney injury","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1593\/neo.13432","article-title":"Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition","volume":"15","author":"Coppock","year":"2013","journal-title":"Neoplasia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41419-021-03588-w","article-title":"FGF21 facilitates autophagy in prostate cancer cells by inhibiting the PI3K-Akt-mTOR signaling pathway","volume":"12","author":"Dai","year":"2021","journal-title":"Cell Death Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"106035","DOI":"10.1016\/j.neubiorev.2025.106035","article-title":"The metabolic basis of cancer-related fatigue","volume":"169","author":"Dantzer","year":"2025","journal-title":"Neurosci. Biobehav Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/nm.4393","article-title":"The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL","volume":"23","author":"Emmerson","year":"2017","journal-title":"Nat. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.cmet.2019.08.019","article-title":"Fibroblast growth factor 21 drives dynamics of local and systemic stress responses in mitochondrial myopathy with mtDNA deletions","volume":"30","author":"Forsstrom","year":"2019","journal-title":"Cell Metab."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/nejmoa2409515","article-title":"Ponsegromab for the treatment of cancer cachexia","volume":"391","author":"Groarke","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bbi.2020.05.043","article-title":"Interleukin 6-independent metabolic reprogramming as a driver of cancer-related fatigue","volume":"88","author":"Grossberg","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.bbrc.2020.04.002","article-title":"Fibroblast growth factor 19 alleviates palmitic acid-induced mitochondrial dysfunction and oxidative stress via the AMPK\/PGC-1alpha pathway in skeletal muscle","volume":"526","author":"Guo","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.cmet.2024.03.013","article-title":"Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8(+)T cells","volume":"36","author":"Hu","year":"2024","journal-title":"Cell Metab."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e58575","DOI":"10.1371\/journal.pone.0058575","article-title":"Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319","volume":"8","author":"Kharitonenkov","year":"2013","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/dom.12408","article-title":"Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function","volume":"17","author":"Kim","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"B16","doi-asserted-by":"publisher","first-page":"111947","DOI":"10.1016\/j.celrep.2022.111947","article-title":"GDF15 neutralization restores muscle function and physical performance in a mouse model of cancer cachexia","volume":"42","author":"Kim-Muller","year":"2023","journal-title":"Cell Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1096\/fj.201701316R","article-title":"FGF21 is induced in cisplatin nephrotoxicity to protect against kidney tubular cell injury","volume":"32","author":"Li","year":"2018","journal-title":"FASEB J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/acn3.51104","article-title":"Accuracy of FGF-21 and GDF-15 for the diagnosis of mitochondrial disorders: a meta-analysis","volume":"7","author":"Lin","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1152\/japplphysiol.00456.2016","article-title":"Fibroblast growth factor 21 is required for beneficial effects of exercise during chronic high-fat feeding","volume":"121","author":"Loyd","year":"2016","journal-title":"J. Appl. Physiol. (1985)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.canlet.2020.11.026","article-title":"FGF21 in obesity and cancer: new insights","volume":"499","author":"Lu","year":"2021","journal-title":"Cancer Lett."},{"key":"B21","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.3390\/ijms241411401","article-title":"Endurance exercise-induced Fgf21 promotes skeletal muscle fiber conversion through TGF-beta1 and p38 MAPK signaling pathway","volume":"24","author":"Luo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1111\/febs.16331","article-title":"FGF signalling facilitates cervical cancer progression","volume":"289","author":"Mahmood","year":"2022","journal-title":"FEBS J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"7432","DOI":"10.1073\/pnas.0701600104","article-title":"BetaKlotho is required for metabolic activity of fibroblast growth factor 21","volume":"104","author":"Ogawa","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10157-024-02490-x","article-title":"An integrated view of cisplatin-induced nephrotoxicity, hepatotoxicity, and cardiotoxicity: characteristics, common molecular mechanisms, and current clinical management","volume":"28","author":"Oliveira","year":"2024","journal-title":"Clin. Exp. Nephrol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1021\/acsptsci.0c00100","article-title":"Optimization of peptide inhibitors of beta-Klotho as antagonists of fibroblast growth factors 19 and 21","volume":"3","author":"Pan","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.3390\/cells10092418","article-title":"The Saga of endocrine FGFs","volume":"10","author":"Phan","year":"2021","journal-title":"Cells"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1038\/s41416-018-0280-x","article-title":"Fibroblast growth factor 21 as a circulating biomarker at various stages of colorectal carcinogenesis","volume":"119","author":"Qian","year":"2018","journal-title":"Br. J. Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/archoto.2009.159","article-title":"Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer","volume":"135","author":"Spanos","year":"2009","journal-title":"Arch. Otolaryngol. Head. Neck Surg."},{"key":"B29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41419-023-06386-8","article-title":"Non-alcoholic fatty liver disease promotes breast cancer progression through upregulated hepatic fibroblast growth factor 21","volume":"15","author":"Sui","year":"2024","journal-title":"Cell Death Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"bqae120","DOI":"10.1210\/endocr\/bqae120","article-title":"Characterization of FGF21 sites of production and signaling in mice","volume":"165","author":"Sullivan","year":"2024","journal-title":"Endocrinology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"18394","DOI":"10.18632\/oncotarget.7817","article-title":"Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients","volume":"7","author":"Tan","year":"2016","journal-title":"Oncotarget"},{"key":"B32","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3389\/fphys.2019.00419","article-title":"FGF21 as modulator of metabolism in health and disease","volume":"10","author":"Tezze","year":"2019","journal-title":"Front. Physiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"100793","DOI":"10.1016\/j.diff.2024.100793","article-title":"Fibroblast growth factor 21","volume":"139","author":"Trusz","year":"2024","journal-title":"Differentiation"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e17868","DOI":"10.1371\/journal.pone.0017868","article-title":"FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways","volume":"6","author":"Wu","year":"2011","journal-title":"PLoS One"},{"key":"B35","doi-asserted-by":"publisher","first-page":"114823","DOI":"10.1016\/j.bcp.2021.114823","article-title":"Activation of activator protein-1-fibroblast growth factor 21 signaling attenuates cisplatin hepatotoxicity","volume":"194","author":"Zhang","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4093\/dmj.2023.0115","article-title":"Mitochondrial stress and mitokines: therapeutic perspectives for the treatment of metabolic diseases","volume":"48","author":"Zhang","year":"2024","journal-title":"Diabetes Metab. J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1800474\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:43:38Z","timestamp":1782452618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1800474\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":36,"alternative-id":["10.3389\/fphar.2026.1800474"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1800474","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"1800474"}}